Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Chief Strategy Officer | February 28, 2011 | March 01, 2011 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | October 22, 2021 | October 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date February 28, 2011 · Filed March 01, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,114.7647 |
Reported balance
After 2011-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2011-02-28 · Exercise / conversion · Acquired 4,650 · Balance 28,114.7647 |
| Common StockSEC Table I · non-derivative | Direct | 26,423.7647 |
Reported balance
After 2011-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2011-02-28 · Tax withholding · Disposed 1,691 · Balance 26,423.7647 F1: Holdings include shares acquired in dividend reinvestment transactions. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2011-02-28 | Direct | 0 |
Reported balance
After 2011-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2011-02-28 · Exercise / conversion · Disposed 4,650 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 1,458.8222 |
Reported balance
Holding disclosure · report date 2011-02-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,458.8222 F2: Includes shares acquired and dividends earned through January 7, 2011, in the MSD Employee Savings and Security Plan, a 401(k) Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 86 |
Reported balance
Holding disclosure · report date 2011-02-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 86 |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Includes shares acquired and dividends earned through January 7, 2011, in the MSD Employee Savings and Security Plan, a 401(k) Plan.
F3: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
SAB Biotherapeutics, Inc.
Report date October 22, 2021 · Filed October 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2031-01-01 | Direct | 69,793 |
Reported balance
After 2021-10-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-22 · Grant · Acquired 69,793 · Balance 69,793 F1: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F2: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, January 1, 2021, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. |
| Earnout Rights (Restricted Stock Units)SEC Table II · derivative / convertible security | Direct | 9,399 |
Reported balance
After 2021-10-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-22 · Grant · Acquired 9,399 · Balance 9,399 F3: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: F4: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
F2: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, January 1, 2021, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.
F3: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows:
F4: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2021 Filed Oct 27, 2021 01:49 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEarnout Rights (Restricted Stock Units) · Derivative | 9,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-026386 · ownership.xml · derivative · entry 2 Turner Mervyn · CIK 0001475383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,399 Underlying: Common Stock · 9,399 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: F4 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F3 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: F4 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F3 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: F4 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. F3 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: F4 · derivative.expiration_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period. Read SEC document |
| October 22, 2021 Filed Oct 27, 2021 01:49 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantEmployee Stock Option (right to buy) · Derivative | 69,793 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001493152-21-026386 · ownership.xml · derivative · entry 1 Turner Mervyn · CIK 0001475383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,793 Underlying: Common Stock · 69,793 shares Expires 2031-01-01 F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F2 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, January 1, 2021, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). F2 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, January 1, 2021, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,650 | $32.19 | $149,683.50 |
DisclosureSEC source: 0001225208-11-007802 · doc4.xml · derivative · entry 5 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,650 shares Expires 2011-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,691 | $32.19 | $54,433.29 |
DisclosureSEC source: 0001225208-11-007802 · doc4.xml · nonDerivative · entry 2 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,423.7647 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007802 · doc4.xml · nonDerivative · entry 1 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,114.7647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2011 Filed Feb 24, 2011 17:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,541 | $32.34 | $114,515.94 |
DisclosureSEC source: 0001225208-11-007026 · doc4.xml · nonDerivative · entry 1 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,464.7647 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/29/08. Performance shares were paid out at 122 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2010 Filed May 11, 2010 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 24,010 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012655 · doc4.xml · derivative · entry 4 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,010 Underlying: Common Stock · 24,010 shares Expires 2020-05-06 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012655 · doc4.xml · derivative · entry 3 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,986 Underlying: Common Stock · 2,986 shares Expires 2013-05-07 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| January 08, 2010 Filed Oct 14, 2010 21:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,688 | $37.72 | $101,391.36 |
DisclosureSEC source: 0001209191-10-050440 · c06892_4x0.xml · nonDerivative · entry 1 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,367.701 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/02/2007. Performance shares were paid out at 120 percent of target awards. Filing is late due to an administrative oversight by the Company. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 24,800 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 18 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2019-04-23 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 24,800 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 17 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2018-02-28 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 16 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2017-03-01 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 13,334 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 15 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 13,334 shares Expires 2016-03-02 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $34.47 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 14 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2016-01-31 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 21,099 | $0.00 Strike: $75.76 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 13 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,099 Underlying: Common Stock · 21,099 shares Expires 2011-03-01 F5 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 12 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2015-02-24 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $28.90 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 11 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2014-10-31 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $47.39 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 10 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2014-05-02 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 9 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2014-02-26 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 25,319 | $0.00 Strike: $62.09 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 8 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2010-02-21 F5 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 26,374 | $0.00 Strike: $49.96 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 7 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,374 Underlying: Common Stock · 26,374 shares Expires 2013-02-27 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 18,989 | $0.00 Strike: $58.91 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 6 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,989 Underlying: Common Stock · 18,989 shares Expires 2012-02-29 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 5 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock · 4,650 shares Expires 2012-04-24 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 16,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 4 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2011-09-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 3 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock · 4,650 shares Expires 2011-02-28 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerCommon Stock | 64 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · nonDerivative · entry 2 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 86 F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Read SEC document |
| November 03, 2009 Filed Nov 9, 2009 16:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock - 401(k) Plan | 1,221.8905 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021927 · doc4.xml · nonDerivative · entry 1 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 1,221.8905 F1 · price: Received as part of the Transactions in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. ("MSD") common stock held under the MSD 401(k) plan. Read SEC document |
| November 03, 2009 Filed Oct 14, 2010 21:28 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock | 16,565.6788 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-10-050439 · c06893_4ax1.xml · nonDerivative · entry 1 Turner Mervyn · CIK 0001475383 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,565.6788 F1 · balance_after: Due to an administrative oversight by the Company, these shares were not reported on original filing. Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.